Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2024/05/068034
CTRI/2024/05/068034
Not yet recruiting
Phase 4

Clinical and Biomarker evaluation of response to oral immunosuppressants in Moderate to Severe Psoriasis - NI

Surbhi Jain Self0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: L409- Psoriasis, unspecified

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: L409- Psoriasis, unspecified
Sponsor
Surbhi Jain Self
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Surbhi Jain Self

Eligibility Criteria

Inclusion Criteria

  • •1\. Clinically diagnosed patients with moderate to severe psoriasis
  • •2\. Patients aged 18 \- 60 years
  • •3\. PASI score of \= 5 or Body surface area involvement of \= 10%
  • •4\. Patients providing informed consent

Exclusion Criteria

  • •1\. Patients with uncontrolled or major forms of psoriasis which are life threatening
  • •2\. Patients on active topical agents
  • •3\. Patients taking other systemic drugs for psoriasis in last 2 months
  • •4\. Patient taking other drugs which can interfere with Methotrexate or Apremilast or Cyclosporine
  • •5\. Patients on biologics within the past 2 weeks
  • •6\. Patients with liver or renal impairment or anaemia or thrombocytopenia or leukopenia
  • •7\. Patients with hepatitis B, C, HIV or TB infection
  • •8\. Patients with a co\-existing comorbidity like diabetes mellitus, uncontrolled hypertension and psychiatric illness
  • •9\. Pregnant and breastfeeding patients

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Early clinical and biomarker responses after treatment in patients with non-segmental vitiligoVitiligo10035023
NL-OMON48618Academisch Medisch Centrum36
Recruiting
Not Applicable
Effect of oral fosfomycin as a step-down treatment for complicated urinary tract infections induced by ESBL-producing enterobacteriaceaeDiseases of the genitourinary system
KCT0007669Chosun University Hospital300
Completed
Phase 2
Preclinical and clinical evaluation of the siddha classical drug ATHIMADHURA KULIGAI(oral administration) along with KADUGU ENNAI (external application) in the management of AUTISM SPECTRUM DISORDER.Health Condition 1: F840- Autistic disorder
CTRI/2022/02/039889DrBTamil Elakkiya40
Active, not recruiting
Phase 1
A study to investigate the clinical and immunological effects on field cancerization in patients treated with PD-1 inhibition for advanced or metastatic cutaneous squamous cell carcinomaadvanced or metastatic cutaneous squamous cell carcinomaMedDRA version: 24.1Level: LLTClassification code 10085908Term: Cutaneous squamous cell carcinomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2021-006372-17-DEMuehlenkreiskliniken AoeR20
Active, not recruiting
Phase 1
DRelapsing Remitting Multiple SclerosisMedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2016-000708-26-ITFONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE50